Handelsbanken Fonder AB Grows Stock Holdings in Cytokinetics, Incorporated $CYTK

Handelsbanken Fonder AB boosted its stake in Cytokinetics, Incorporated (NASDAQ:CYTK) by 63.8% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 405,000 shares of the biopharmaceutical company’s stock after acquiring an additional 157,700 shares during the period. Handelsbanken Fonder AB owned 0.33% of Cytokinetics worth $34,502,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its position in Cytokinetics by 1.6% in the 4th quarter. Vanguard Group Inc. now owns 12,048,131 shares of the biopharmaceutical company’s stock valued at $765,538,000 after buying an additional 191,336 shares during the last quarter. Royce & Associates LP boosted its holdings in shares of Cytokinetics by 44.3% in the fourth quarter. Royce & Associates LP now owns 144,426 shares of the biopharmaceutical company’s stock valued at $9,177,000 after acquiring an additional 44,343 shares in the last quarter. Norges Bank purchased a new stake in shares of Cytokinetics in the fourth quarter valued at about $51,281,000. GW&K Investment Management LLC increased its stake in shares of Cytokinetics by 161.5% during the fourth quarter. GW&K Investment Management LLC now owns 472,363 shares of the biopharmaceutical company’s stock worth $30,015,000 after acquiring an additional 291,693 shares during the period. Finally, Eventide Asset Management LLC raised its holdings in Cytokinetics by 181.9% during the fourth quarter. Eventide Asset Management LLC now owns 479,611 shares of the biopharmaceutical company’s stock worth $30,473,000 after purchasing an additional 309,503 shares in the last quarter.

Cytokinetics News Roundup

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: HC Wainwright raised its earnings forecasts and maintained a Buy rating. The analyst improved its Q3 2026 EPS estimate to $(1.65) from $(1.80), Q4 to $(1.55) from $(1.86), and full-year 2026 to $(6.38) from $(6.86). HC Wainwright also retained a $140 price target, well above recent trading levels, signaling confidence in Cytokinetics’ development pipeline and future prospects.
• Positive Sentiment: Other analysts have recently increased their price targets. Citizens JMP raised its target to $110, Truist Financial lifted its target to $112, and UBS upgraded the stock to Buy with a $115 target. The analyst consensus remains “Moderate Buy,” with an average target of approximately $101.15. Cytokinetics Price Target Raised to $110 Cytokinetics Price Target Raised to $112
• Neutral Sentiment: Reported short-interest data showed no measurable short position. The filing listed short interest at zero shares and a zero-day short-interest ratio, but the reported percentage change was unavailable. Consequently, the data provides little actionable information about potential short-covering or bearish positioning.
• Negative Sentiment: CEO Robert Blum sold 7,500 shares worth approximately $575,700. The transaction reduced his direct holdings by 1.95%, which can create a modest negative signal for investors. However, the sale was executed under a pre-arranged Rule 10b5-1 trading plan, making it less indicative of a discretionary bearish view. Insider Selling: Cytokinetics CEO Sells 7,500 Shares

Cytokinetics Price Performance

Shares of NASDAQ CYTK opened at $76.45 on Wednesday. The company has a market cap of $9.51 billion, a PE ratio of -10.59 and a beta of 0.38. Cytokinetics, Incorporated has a 12 month low of $33.17 and a 12 month high of $88.31. The company has a 50-day simple moving average of $79.10 and a 200-day simple moving average of $71.15.

Cytokinetics (NASDAQ:CYTK) last posted its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($1.50) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.63) by $0.13. The firm had revenue of $28.62 million during the quarter, compared to analyst estimates of $17.59 million. During the same period in the prior year, the firm earned ($1.12) EPS. The business’s quarterly revenue was down 57.1% on a year-over-year basis. On average, analysts anticipate that Cytokinetics, Incorporated will post -6 EPS for the current year.

Insider Buying and Selling at Cytokinetics

In other news, EVP Andrew Callos sold 15,000 shares of the firm’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $74.08, for a total transaction of $1,111,200.00. Following the sale, the executive vice president owned 58,555 shares in the company, valued at $4,337,754.40. This trade represents a 20.39% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Robert I. Blum sold 7,500 shares of Cytokinetics stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $84.92, for a total value of $636,900.00. Following the completion of the sale, the chief executive officer directly owned 377,830 shares of the company’s stock, valued at approximately $32,085,323.60. This represents a 1.95% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 122,679 shares of company stock valued at $9,701,754 over the last quarter. 2.60% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several analysts have recently commented on CYTK shares. Stifel Nicolaus raised their price target on Cytokinetics from $98.00 to $108.00 and gave the company a “buy” rating in a report on Wednesday, May 6th. Royal Bank Of Canada dropped their price objective on Cytokinetics from $117.00 to $112.00 and set an “outperform” rating on the stock in a report on Friday. Wall Street Zen cut Cytokinetics from a “hold” rating to a “sell” rating in a research report on Saturday. UBS Group raised Cytokinetics from a “neutral” rating to a “buy” rating and raised their target price for the company from $69.00 to $115.00 in a report on Monday, June 29th. Finally, Needham & Company LLC boosted their target price on shares of Cytokinetics from $102.00 to $112.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $101.15.

Cytokinetics Company Profile

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.